Quince Therapeutics Sets Phase 3 NEAT Readout Mid-Q1 2026 Targeting $1B Orphan Market
Quince Therapeutics will report pivotal Phase 3 NEAT trial results in Ataxia-Telangiectasia mid-Q1 2026 for its eDSP lead asset targeting a $1B orphan market lacking approved therapies. The NEAT trial is 90% powered for significance in 6-9 year-olds after redesign to correct prior flaws and enjoys strong regulatory alignment.
1. Pivotal Phase 3 NEAT Trial Readout Expected Mid-Q1 2026
Quince Therapeutics is positioned for a major catalyst with the pivotal Phase 3 NEAT trial in Ataxia-Telangiectasia (A-T) slated to read out in mid-Q1 2026. The trial, designed to address previous design deficiencies, enrolls children aged 6 to 9 and is powered at 90% to detect statistically significant improvements in neurological function over a six-month treatment period. Regulatory agencies have provided strong alignment on primary and secondary endpoints, and the company has secured trial sites across North America and Europe, targeting full enrollment of 120 patients by the end of 2025.
2. eDSP Platform Targets >$1 Billion Orphan Market
Quince’s lead asset, EryDex (eDSP), employs an autologous red-blood-cell delivery system to provide sustained corticosteroid release with a reduced toxicity profile. The company projects that this technology could penetrate a rare-disease market estimated at over $1 billion annually, encompassing pediatric neurodegenerative disorders beyond A-T. EryDex’s one-hour automated preparation and once-monthly dosing regimen are designed to improve patient compliance and reduce systemic side effects compared to daily oral steroids.
3. Consensus Rating and Analyst Price Objective
Seven brokerages currently cover Quince Therapeutics, issuing a consensus rating of Moderate Buy. Four analysts recommend a Buy, one a Strong Buy, one a Hold and one a Sell. The average twelve-month price objective stands at $8.00, reflecting upside potential based on upcoming clinical milestones. Notably, D. Boral Capital raised its target from $4.00 to $5.00 in December, while Citigroup reaffirmed a Market Outperform rating in early January.
4. Institutional Investors Increase Exposure
During the second and third quarters of 2025, multiple hedge funds and institutional investors boosted their stakes in Quince. XTX Topco Ltd initiated a position valued at $37 000, while GSA Capital Partners LLP expanded its holding by 158%, acquiring 53 417 additional shares to reach a total stake valued at $142 000. Bridgeway Capital Management LLC increased its shares by 20.9%, and Union Square Park Capital Management LLC grew its position by 86%, signaling growing confidence among sophisticated investors in Quince’s clinical and platform prospects.